This immunotherapy is based on the discovery by the founding team's members of the tumor antigen ppCT (Preprocalcitonin), a precursor of the hormone calcitonin (CT).

They demonstrated that ppCT, which is expressed or over-expressed in several human lung tumor types, is capable of inducing a specific immune response in many lung cancer patients and constitutes a promising target for cancer immunotherapy approaches.
The ultimate goal is to develop a personalized therapeutic vaccine composed not only of ppCT antigen, but also of neoepitopes from mutated antigens identified in the tumor of each patient, which will be the heart of the ElyssaTech® platform.

This technology differs from all other competing immunotherapy approaches by its mode of action as it will allow destruction of immune escaped tumors and thus its use in multi-resistant patients.